Nordic Nanovector Announces that the data from the LYMRIT 37

OSLO, Norway, June 10, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces an update from the LYMRIT 37-05 Phase 1 trial investigating Betalutin (177Lu lilotomab satetraxetan)

Related Keywords

Norway , Japan , Austria , Vienna , Wien , Gomez Codina , Erik Skullerud , Malene Brondberg , Frazer Hall Medi , European Hematology Association , Nordic Nanovector , Abstract Code , Stem Cell Transplantation , South Asian , Disease Landscape , Frazer Hall , Securities Trading , Nordic , Nanovector , Nnounces , Data , Rom , Ymrit , Hase , Trial , Etalutin , Relapsed , Refractory , Diffuse , Barge , Fell , Lymphoma , Dlbcl , Resented , 022 , Meeting ,